Chardan analyst Keay Nakae raised the firm’s price target on Dyne Therapeutics to $31 from $20 and keeps a Buy rating on the shares following the Q4 report. The analyst has increased confidence in the company’s platform following the positive first in human data for its lead assets, DYNE-101 and DYNE-251. The initial safety and efficacy data from these two programs provide important clinical proof of concept for Dyne’s Force platform to successfully deliver to ex-hepatic targets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DYN:
- Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
- Dyne Therapeutics price target raised to $29 from $27 at Piper Sandler
- Dyne Therapeutics price target raised to $41 from $35 at Stifel
- Dyne Therapeutics files automatic mixed securities shelf
- Dyne Therapeutics price target raised to $47 from $44 at Oppenheimer
